Lipocine (LPCN) Current Deferred Revenue (2024 - 2025)
Lipocine's (LPCN) quarterly Current Deferred Revenue came in at $320000.0 in Q4 2025, little changed YoY from $320000.0 in Q4 2024, and little changed on a QoQ basis from $320000.0 in Q3 2025.
Lipocine (LPCN) Current Deferred Revenue (2024 - 2025) Analysis & Trends
Lipocine (LPCN) has 2 years of Current Deferred Revenue data on file, last reported at $320000.0 in Q4 2025.
- Quarterly Current Deferred Revenue changed 0.0% year-over-year to $320000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $320000.0 (changed 0.0% YoY) and the FY2025 annual result came in at $320000.0, changed 0.0% from the prior year.
- Current Deferred Revenue was little changed at $320000.0 in Q4 2025, from $320000.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $320000.0 in Q4 2024 to a low of $320000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 320,000.00 |
| Sep 30, 2025 | 320,000.00 |
| Jun 30, 2025 | 320,000.00 |
| Mar 31, 2025 | 320,000.00 |
| Dec 31, 2024 | 320,000.00 |